Armenia grants Agenus first marketing approvals for Botvymo-Evamplix combo in MSS metastatic colorectal cancer
Bitget2026/10/08 11:30Armenia granted the first marketing authorizations worldwide for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab) as a combination regimen. Clearance covers previously treated adults with MSS metastatic colorectal cancer without active liver metastases. Authorizations took effect Oct. 2, 2026; approvals are conditional for one year, renewable with annual clinical updates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080730BIZWIRE_USPR_____20261008_BW022628) on October 08, 2026, and is solely responsible for the information contained therein.
- Armenia granted the first marketing authorizations worldwide for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab) as a combination regimen.
- Clearance covers previously treated adults with MSS metastatic colorectal cancer without active liver metastases.
- Authorizations took effect Oct. 2, 2026; approvals are conditional for one year, renewable with annual clinical updates.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese and South Korean stock markets open

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Amid opposition to data centers, Musk doubles down: SpaceX (SPCX.US) plans to build a $24 billion computing center and gas power plant in Texas.
According to a public hearing notice published on the Starbase website, SpaceX plans to build, own, and operate a gas-fired power plant and a supercomputing facility at its company town in Starbase, Texas.